Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT01768364
Other study ID # 2012/953
Secondary ID
Status Not yet recruiting
Phase N/A
First received January 14, 2013
Last updated January 14, 2013
Start date January 2013
Est. completion date April 2016

Study information

Verified date January 2013
Source University Hospital, Akershus
Contact Tor Erik Sand, MD, PhD
Email tor.erik.sand@ahus.no
Is FDA regulated No
Health authority Norway: Ethics Committee
Study type Interventional

Clinical Trial Summary

Is there anything to gain in giving antibiotics as prophylaxis when removing ureteric stents cystoscopically after stone surgery?


Description:

Many patients undergoing stone surgery receive a ureteric stent that should be removed after 14 days. This stent is removed cystoscopically and today this is done without giving antibiotics. Some patients get urinary tract infections subject to this. However the investigators do not know how many of these patients get UTI as most are followed by their primary care doctor. With this study the investigators would like to find out whether it is possible to avoid such infections and also find out how many actually do get infected.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 124
Est. completion date April 2016
Est. primary completion date January 2016
Accepts healthy volunteers No
Gender Both
Age group N/A and older
Eligibility Inclusion Criteria:

- stone surgery patients with ureteric stent that should be removed after 14 days

Exclusion Criteria:

- ongoing antibiotic treatment, allergy to trimetoprim-sulfa

Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention


Related Conditions & MeSH terms

  • Ureteric Stent After Stone Surgery

Intervention

Drug:
Trimetoprim-Sulfa (Bactrim)

Other:
No antibiotics


Locations

Country Name City State
Norway Akershus University Hospital Lorenskog

Sponsors (1)

Lead Sponsor Collaborator
Tor Erik Sand

Country where clinical trial is conducted

Norway, 

Outcome

Type Measure Description Time frame Safety issue
Primary 14 days infection rate w/wo antibiotics 14 days No
Secondary infection rate with ureter stent wo antibiotics 14 days No